Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study

Digestive and Liver Disease

Volumn 46, Issue 2, 2014, Pages 182-186

  Cascinu, Stefano ^a   Berardi, Rossana ^a   Sobrero, Alberto ^b   Bidoli, Paolo ^c   Labianca, Roberto ^d   Siena, Salvatore ^e   Ferrari, Daris ^f   Barni, Sandro ^g   Aitini, Enrico ^h   Zagonel, Vittorina ⁱ   Caprioni, Francesco ^b   Villa, Federica ^c   Mosconi, Stefania ^d   Faloppi, Luca ^a   Tonini, Giuseppe ^j   Boni, Corrado ^k   Conte, Pierfranco ^l   Di Costanzo, Francesco ^m   Cinquini, Michela ⁿ  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

^d OSPEDALI RIUNITI   (Italy)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f SAN PAOLO HOSPITAL   (Italy)

^g TREVIGLIO HOSPITAL   (Italy)

^h CARLO POMA HOSPITAL   (Italy)

ⁱ VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^j UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^k S MARIA NUOVA HOSPITAL   (Italy)

^l UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^m CAREGGI UNIVERSITY HOSPITAL   (Italy)

ⁿ MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

more..

Author keywords

Cisplatin; Gemcitabine; Pancreatic cancer; Phase II study; Sorafenib

Indexed keywords

CISPLATIN; GEMCITABINE; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OPEN STUDY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

CISPLATIN; GEMCITABINE; PANCREATIC CANCER; PHASE II STUDY; SORAFENIB;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NIACINAMIDE; PANCREATIC NEOPLASMS; PHENYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84893652695     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.09.020     Document Type: Article

References (29)

1. Burris H.A., Moore M.J., Andersen J., et al. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology 1997, 15:2403-2413.
2. Hidalgo M. Pancreatic cancer. New England Journal of Medicine 2010, 362:1605-1617.
3. Wong H.H., Lemoine N.R. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nature Reviews Gastroenterology & Hepatology 2009, 6:412-422.
4. Cascinu S., Berardi R., Labianca R., et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with a advanced pancreatic cancer: a randomised, multicentre, phase II study. Lancet Oncology 2008, 9:39-44.
5. Philip P.A., Benedetti J., Corless C.L., et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Sowthwest Oncology Group-directed Intergroup Trial S0205. Journal of Clinical Oncology 2010, 28:1-6.
6. Kindler H.L., Ioka T., Richel D.J., et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncology 2011, 12:256-262.
7. Kindler H.L., Niedzwiecki D., Hollis D., et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase II trial of the Cancer and leukaemia Group B (CALGB 80303). Journal of Clinical Oncology 2010, 28:3617-3622.
8. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 2007, 25:1960-1966.
9. Wilhelm S.M., Adnane L., Newell P., Villanueva A., Llovet J.M., Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular Cancer Therapeutics 2008, 7:3129-3140.
10. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad oral antitumor activity and targets the RAF/MEK/ERK pathway and receptors tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 2004, 64:7099-7109.
11. Siu L.L., Awada A., Takimoto C.H., et al. Phase I of sorafenib and gemcitabine in advanced solid tumours with an expanded cohort in advanced pancreatic cancer. Clinical Cancer Research 2006, 12:144-151.
12. Lee J.K., Capanu M., O'Reilly E.M., et al. Phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. Journal of Cancer 2013, 109:915-919.
13. Paz-Ares L.G., Biesma B., Heigener D., et al. NSCLC [non-small-cell lung cancer] Research Experience Utilizing Sorafenib (NExUS) Investigators Study Group. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. Journal of Clinical Oncology 2012, 30:3084-3092.
14. Schultheis B., Kummer G., Zeth M., et al. Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology 2012, 69:333-339.
15. Sultana A., Smith C.T., Cunningham D., Starling N., Neoptolemos J.P., Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. Journal of Clinical Oncology 2007, 25:2607-2615.
16. Banu E., Banu A., Fodor A., et al. Meta-analysis of randomized trials comparing gemcitabine-based chemotherapy versus gemcitabine alone in patients with advanced or metastatic pancreatic cancer. Drugs Aging 2007, 24:865-879.
17. Liang H. Comparing gemcitabine-based combination chemotherapy with gemcitabine alone in inoperable pancreatic cancer: a meta-analysis. Journal of Clinical Oncology 2005, 23:335s. [suppl; abstr 4110].
18. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 2004, 92:205-216.
19. Colucci G., Labianca R., Di Costanzo F., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. Journal of Clinical Oncology 2010, 28:1645-1651.
20. Kindler H.L., Wroblewski K., Wallace J.A., et al. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago phase II consortium. Investigational New Drugs 2012, 30:382-386.
21. Gonçalves A., Gilabert M., François E. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Annals of Oncology 2012, 23:2799-2805.
22. Vincent P., Zhang X., Chen C.M. Preclinical chemotherapy with the Raf kinase inhibitor BAY43-9006 in combination with gefitinib, vinorelbine, gemcitabine or doxorubicin. Proceedings of the American Association for Cancer Research 2003, 44:164.
23. Ricciardi S., Mey V., Nannizzi S., Pasqualetti G., Crea F., Del Tacca M., Danesi R. Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells. Chemotherapy 2010, 56:303-312.
24. Ulivi P., Arienti C., Zoli W., et al. In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells. Current Cancer Drug Targets 2010, 10:600-610.
25. Van Cutsem E., van de Velde H., Karasek P., et al. Phase III trial of gemcitabine plus tipifarnib compares with gemcitabine plus placebo in advanced pancreatic cancer. Journal of Clinical Oncology 2004, 22:1430-1438.
26. Ji Z., Mei F.C., Xie J., Cheng X. Oncogenic KRAS activates hedgehog signalling pathway in pancreatic cancer cells. Journal of Biological Chemistry 2007, 28:1048-1055.
27. Scagliotti G., Novello S., von Pawel J., et al. Phase III sorafenib of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. Journal of Clinical Oncology 2010, 28:1835-1842.
28. Sun W., Powell M., O'Dwyer P.J., Catalano P., Ansari R.H., Benson A.B. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. Journal of Clinical Oncology 2010, 28:2947-2951.
29. Blumenschein G.R, Gatzemeier U., Fossella F., et al. Phase II multicenter uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory advanced non-small-cell lung cancer. Journal of Clinical Oncology 2009, 27:4274-4280.